Roche: latest data for MS drug
(CercleFinance.com) - Roche has announced the latest data from the phase III OCARINA II study.
The study results demonstrate the effect of OCREVUS (ocrelizumab) as an investigational 10-minute subcutaneous injection on pharmacokinetic, biomarker and MRI measures in patients with relapsing-remitting or primary-progressive multiple sclerosis (RMS or PPMS).
The data will be presented at the 9th joint ECTRIMS-ACTRIMS (European and American Committees for Treatment and Research in Multiple Sclerosis) meeting.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study results demonstrate the effect of OCREVUS (ocrelizumab) as an investigational 10-minute subcutaneous injection on pharmacokinetic, biomarker and MRI measures in patients with relapsing-remitting or primary-progressive multiple sclerosis (RMS or PPMS).
The data will be presented at the 9th joint ECTRIMS-ACTRIMS (European and American Committees for Treatment and Research in Multiple Sclerosis) meeting.
Copyright (c) 2023 CercleFinance.com. All rights reserved.